ALK (ALK-B.CO / OMX:ALK B / AKABY / AKBLF) today announced that due to the US government shutdown, the US Food and Drug Administration (FDA) has temporarily postponed the Allergenic Products Advisory Committee meeting scheduled for 6 November 2013 to discuss the Biologic License Application (BLA) for the investigational grass allergy immunotherapy (AIT) tablet. The FDA has not yet confirmed a new date for the Advisory Committee meeting. ALK will provide an update when additional information becomes available. - See more at: http://www.globenewswire.com/news-release/2013/10/08/578902/0/en/FDA-postpones-Advisory-Committee-meeting-for-grass-AIT-tablet-due-to-US-government-shutdown.html#sthash.wjCSNgaY.dpuf
Help employers find you! Check out all the jobs and post your resume.
